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ABSTRACT

Introduction
Inflammatory

bowel

disease

(IBD)

describes

gastrointestinal

inflammatory diseases Crohn’s disease (CD) and ulcerative colitis (UC). The
inflammation associated with CD can penetrate deep layers of gastrointestinal
tissue anywhere along the gastrointestinal tract. Pharmaceutical therapy
options for CD include aminosalicylates, corticosteroids, antimicrobials,
immunomodulators, and biologics. The step-up (SU) treatment strategy for CD
begins with anti-inflammatory agents (aminosalicylates, corticosteroids, and
antimicrobials), and progresses to immunomodulators and biologics if disease
control is not achieved. Conversely, with top-down (TD) therapy strategy,
patients initiate CD medication treatment with immunomodulators and biologics
and use anti-inflammatory agents as second-line options. Presently, limited
evidence exists characterizing the utilization and short-term costs related to SU
and TD therapy in CD.
Objective
The objective of this thesis research was to observe patient/disease
characteristics in patients initiating CD pharmaceutical treatment with SU and
TD therapy, and to examine predictors of increased first-year healthcare
expenditures in a real-world setting.

Methods

This was a retrospective, cohort analysis of Optum’s de-identified
Clinformatics® Data Mart Database examining patients with CD who were
newly initiated on medication therapy from 2010 to 2018. Patients with CD were
identified as having two International Classification of Diseases (ICD) codes for
CD that were at least 30 days apart. The first CD-ICD code was considered the
index diagnosis date. The SU and TD cohorts were defined based on
medications for CD dispensed in the 60-day exposure period after the index
diagnosis date. We examined 365 days prior to the index diagnosis to exclude
patients not newly initiated on therapy, and 365 days after the exposure period
to examine costs. We conducted a descriptive analysis comparing the SU and
TD cohorts and used t-tests, chi-squared tests, and analyses of variance
(ANOVA) to test the statistical significance of group differences. Predictors of
per-patient average adjusted CD-specific healthcare cost were estimated using
a generalized linear model.
Results
We identified 3,157 patients newly initiating medication therapy for CD,
with 2,392 patients in the SU cohort and 765 patients in the TD cohort. The SU
cohort consisted of a larger proportion of females than the TD cohort (55.02%,
49.67%, respectively, p=0.0009) and the mean age in the SU cohort was higher
than the TD cohort (48.9 years, 39.8 years, respectively, p<0.001). SU therapy
was the dominant treatment strategy utilized each year of our study period, but
the proportion of TD therapy utilized increased over time from 17% in 2011 to
31% in 2017 (p<0.0001). Furthermore, the TD strategy was associated with

higher overall and CD-specific costs in the follow-up period (p<0.0001)
compared to the SU cohort. Treatment strategy, age group, disease location,
GI-related hospitalization prior to diagnosis, payer, and diagnosis year were
significant predictors of CD direct healthcare costs in the generalized linear
model. Patients initiating CD medication treatment with TD therapy had a followup adjusted average per-patient CD-specific direct healthcare cost of 149.78%
($1,230.26) higher than patients who initiated with SU therapy.
Discussion and Conclusion
To our knowledge, this is the first study to use a large administrative claims
database to compare the utilization and first-year healthcare expenditure among
patients initiating medication therapy for CD with either SU or TD approach. We
found that while the SU approach was the dominant treatment strategy, the
proportion of TD therapy utilization increased over time. Furthermore, TD was
associated with a higher overall and CD-specific cost in the year following
treatment initiation. Further research is needed to determine the long-term
overall healthcare costs associated with these strategies.
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CHAPTER 1

INTRODUCTION

Inflammatory bowel disease (IBD) is a gastrointestinal inflammatory
disease, characterized by relapsing intestinal inflammation and tissue damage.
In the gastrointestinal tract, the immune system normally plays an important role
in combating pathogenic bacteria or viruses ingested. In patients with IBD,
however, the immune system response is exaggerated and causes damage to
the gastrointestinal tissue. This damage further triggers an inflammatory
response of the immune system to repair the tissue, leading to a chronic cycle
of damage and inflammation in the gastrointestinal tissue. 1,2 IBD describes two
chronic inflammatory gastrointestinal conditions, Crohn’s disease (CD) and
ulcerative colitis (UC). CD can affect any part of the gastrointestinal tract (from
mouth to anus), most commonly the small and large intestines. Unlike the
continuous nature of UC, CD occurs in patches along the gastrointestinal tract
and penetrates the deep layers of gastrointestinal tissue. Common symptoms
of

CD

include

persistent

diarrhea,

abdominal

pain,

gastrointestinal

bleeding/bloody stools, weight loss, malnutrition, and fatigue. 1-2 Irritable bowel
syndrome (IBS), though similar to IBD in symptoms, is not associated with
inflammation and damage to the gastrointestinal tissue.2
Approximately 3 million US adults (1.3% of the US adult population)
reported a diagnosis of IBD (CD or UC) in the 2015 National Health Interview
Survey (NHIS).3,4 The prevalence of both CD and UC was higher in adults ≥45
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years of age and among non-Hispanic whites.4 Furthermore, the adjusted
incidence of CD was estimated at 10.7 cases (95% CI: 9.1, 12.3) per 100,000
person-years using Rochester Epidemiology Project data from 2000 to 2010;
the estimated adjusted prevalence of CD on January 1, 2011 was 246.7 cases
(95% CI: 221.7, 271.8) per 100,000 persons.5 CD has a bimodal distribution for
age of onset, with ages 20-35 and 50-65 having the highest incidence rates.5-8
Rates of CD-related hospitalizations (CD listed as primary diagnosis) increased
from 44.2 per 100,000 US population in 2003 to 59.7 per 100,000 in 2013, based
on an analysis of the Healthcare Cost and Utilization Project (HCUP) National
Inpatient Sample (NIS) data from 2003 to 2013. 9 Among the CD-related
hospitalizations in 2013,

colorectal resection

occurred

in 12.8% of

hospitalizations, small bowel resections occurred in 3.9% of hospitalizations,
and fistula repairs occurred in 2.0 % of hospitalizations.9
Medication Therapy Guidelines and Recommendations
Medication therapy options for CD include aminosalicylates, corticosteroids,
antimicrobials, immunomodulators, and biologics (see Table 1 for CD-indicated
medications).10-14 Aminosalicylate agents are anti-inflammatory agents that can
be taken orally or topically (suppositories or enemas). Corticosteroids suppress
the immune system systematically, and are generally not recommended for
long-term daily therapy.1,10-14 Antimicrobial agents, specifically metronidazole
and ciprofloxacin, are indicated as anti-inflammatory agents that eliminate
bacterial overgrowth and associated antigenic triggers to decrease inflammation,
but

have

limited

evidence

of

benefit

2

over

placebo

in

CD.10-14

Immunomodulator/antimetabolite

agents,

specifically

thiopurines,

and

methotrexate, are systemic therapies indicated for CD to decrease immune
system and inflammation activity. Lastly, biologic agents indicated for CD have
immunomodulatory mechanisms of action, such as tumor necrosis factor (TNF)alpha inhibitors, Janus Kinase (JAK) inhibitors, adhesion inhibitors, and
interleukin (IL)-23 inhibitors.1,10-14
Guideline recommendations for treating CD include lifestyle changes,
medication therapy, and surgery.10-14 Medication therapy goals for CD are to
induce and maintain remission of the inflammatory processes, achieve mucosal
healing, control symptoms, and prevent complications of CD such as strictures
and fistulas.10-11 Recommendations for initial medication therapy in CD differ
based on the severity of disease presentation and risk of developing
complications.10-14 For mild disease, the American College of Gastroenterology
(ACG) and American Gastroenterological Association (AGA) recommends
medication therapy with either mesalamine, sulfasalazine, budesonide and/or
antibiotics.10-14 The ACG 2009 guidelines recommended mesalamine,
sulfasalazine, or metronidazole, but note that mesalamine and metronidazole
have weaker evidence.10 The ACG 2018 guidelines recommend sulfasalazine
and budesonide for initial treatment of mild/moderate CD, and state mesalamine,
ciprofloxacin, and metronidazole are not recommended for induction treatment
in mild/moderate disease for most patients due to limited evidence of benefit.11
The AGA guidelines recommend budesonide or prednisone with optional
azathioprine treatment for mild/low-risk disease.12-14
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For moderate/severe CD, corticosteroids may be utilized to attain initial
disease control and induce remission, but are not recommended for long-term
therapy.10-14 The AGA defines moderately severe CD as disease requiring
systemic corticosteroids for symptom control.12-14 The ACG and AGA guidelines
recommend using aminosalicylates, immunomodulators, and/or biologic agents
as medication therapy to maintain remission for moderate/severe CD. Per the
ACG 2009 guidelines, azathioprine and 6-mercaptopurine were recommended
to maintain a steroid-induced remission, and methotrexate was recommended
for steroid-dependent and steroid-refractory CD.10 The 2009 ACG guidelines
recommended anti-TNF monoclonal therapy only in patients who fail therapy
with corticosteroids or immunosuppressive agents. The 2018 ACG guidelines
similarly recommend immunosuppressive agents as initial therapy, but also
endorse anti-TNF therapy, anti-integrin therapy (vedolizumab), and natalizumab
therapy as the first medication treatment option or in patients unresponsive to
corticosteroids and immunomodulators; ustekinumab is recommended only for
patients failing corticosteroids, thiopurines, methotrexate, or anti-TNF
inhibitors.11 The AGA guidelines recommend anti-TNF inhibitors over thiopurine
monotherapy in patients with moderately severe Crohn’s disease “despite
standard therapies.”12-14
Top-Down and Step-Up Treatment Sequencing
Traditionally, treatment for CD begins with anti-inflammatory agents
(aminosalicylates, corticosteroids, and antimicrobials), and progresses to
immunomodulatory agents and biologics if disease control is not achieved. This
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treatment sequence has been termed step-up (SU) therapy.1,15-18 Of note, step
therapy, while similar to step-up therapy in choice of medication order, is guided
by managing medication costs for payers and may require patients to fail lowercosting anti-inflammatory agents before trying higher-costing biologic agents.
As the development and approval of biologics and immunomodulating agents
increases for CD, clinical experts are investigating and, in some instances,
recommending early-biologic or top-down (TD) therapy sequences for certain
patients and disease severities.11-14 With TD treatment sequencing, patients
receive the traditionally advanced therapies, such as biologics and
immunomodulators, as their initially prescribed therapy and use antiinflammatory agents (aminosalicylates, corticosteroids, and antimicrobials) as a
secondary therapy, if needed.1,15-18
The use of TD therapy in Crohn’s disease has been debated for over a
decade.19 While evidence exists showing an association between TD therapy
and disease control, reduced relapses, and symptom improvements in CD,
clinical experts hesitate to embrace widespread TD therapy use because of the
risks associated with TD therapy, the lack of definitive evidence that TD therapy
modifies the clinical course of disease, and the costs attributed with TD
medication.20-27 The adverse reactions of the immunomodulators indicated for
CD include increased risk of infection, hepatitis, bone marrow suppression,
pancreatitis, and lymphoma.24,28,29 The biologics indicated for CD are
associated with an increased risk of infection, malignancy, demyelinating
disorders, autoimmunity, and worsening of congestive heart failure. 23-26
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Conversely, anti-inflammatory agents (aminosalicylates, corticosteroids, and
antimicrobials) are considered less toxic and have favorable safety profiles
compared to TD therapies.24 Additionally, the efficacy of the TD therapies were
demonstrated using surrogate endpoints (mucosal healing and symptom control)
to represent decreased intestinal inflammation and associated complications
(ulcerations, bleeding, fistula formation, and fibrosis).24 However, these
surrogate endpoints may be too short-term to account for complications of CD
that evolve over a patient’s lifetime.21,27 In rheumatoid arthritis, TD therapy is a
widely accepted treatment pattern supported by radiographic evidence of
prevention or decreased progression of joint erosion, which modifies the course
of the disease.27,30 Experts have postulated that TD therapy may not have
demonstrated disease modification in CD, and speculated a disconnect
between the mucosal healing endpoint and symptom control.24,27,31 Furthermore,
in terms of cost, the prices and medication-associated healthcare utilization
related to TD therapy may have substantial budget implications for payers,
meanwhile SU therapies have generic options and are generally less costly.32
The economic value of medication therapy and controlling inflammation in
CD is reflected in costs of hospital/emergency department utilization, outpatient
healthcare visits, and surgical procedures over the patient’s lifetime.33,34 Though
short-term costs incurred from medications and associated healthcare utilization
can be substantial, the expected decreased healthcare utilization over the
patient’s lifetime may ultimately yield cost-savings for the healthcare system.3337

However, since a single payer typically does not cover a patient for the
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entirety of a patient’s lifetime, an individual payer may not realize the long-term
economic benefits associated with utilizing expensive, aggressive therapies
early in a patient’s disease course.
Economic evaluation studies comparing SU to TD therapy in CD showed
that cost-effectiveness was not observed in short time horizons (less than 5
years) or in all disease severities; moderate/severe CD has a greater potential
for decreased healthcare utilization in the long-term (5 years) with early
aggressive medication therapy to attain remission compared to mild
disease.36,37 To our knowledge, no study has examined the first-year healthcare
expenditure among patients initiating medication therapy for CD with either a
SU or TD therapy in a large administrative claims database. These short-term
costs are important for payers to understand when creating coverage policies
for optimal healthcare resource utilization.
Objective
The goal of this thesis research was to examine utilization patterns and
short-term healthcare expenditures associated with initiating medication
therapy for CD with either SU or TD therapy in a real-world setting. This
research ascertained how often and in which patient/disease characteristics CD
pharmaceutical treatment was initiated with either SU or TD therapy.
Furthermore, this research examined the difference in the average per-patient
healthcare expenditure in the first year following medication initiation with SU or
TD therapy, adjusting for demographic and clinical factors.
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CHAPTER 2

REVIEW OF LITERATURE

Evidence Assessing Top-Down Therapy in Crohn’s Disease
The TOP-DOWN trial was an open-label, randomized clinical trial of early
immunosuppression therapy compared to conventional management in patients
with CD in Europe from May 2001 to January 2004. Patients aged 16-75 years
who had been diagnosed with CD within 4 years of the study period and who
were not exposed to corticosteroids, antimetabolites, or biological agents prior
to entering the study were included. In the early immunosuppression therapy
cohort, 65 patients with CD received infliximab and azathioprine as initial
pharmaceutical therapy. Conversely, 64 patients with CD in the conventional
management cohort received methylprednisolone or budesonide for induction
therapy. This trial was the first to show that medication therapy with early
immunosuppressive agents achieved remission in more patients at 26 and 52
weeks after therapy initiation than conventional therapy for CD. The absolute
difference in remission rates between immunosuppression and conventional
therapy was 24.1% (39/65 [60%] and 23/64 [35.9%], respectively, p=0.0062) at
26 weeks, and 19.3% (40/65 [61.5%] and 27/64 [42.2%], respectively, p=0.0278)
at 52 weeks.38
Hoekman et al. conducted a follow-up retrospective chart review of patients
enrolled in the TOP-DOWN trial38, to compare long-term outcomes of SU and
TD therapy. After the 2-year TOP-DOWN trial, patients were treated by their
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physicians, therefore the cohort assignment for this follow-up study was based
on intent-to-treat from the original study. After a median follow-up of 8 years,
the researchers found clinical remission rates of 70% and 73% in the SU and
TD cohorts, respectively, (p=0.85). Furthermore, the median time to flare was
shorter in the SU cohort than the TD cohort (five semesters, nine semesters,
respectively, p=0.01). The researchers also found no significant difference
between the SU and TD cohorts for time to CD hospitalization (13 semesters,
14 semesters, respectively, p=0.30) and time to CD surgery (14 semesters, 15
semesters, respectively, p=0.25).39
The REACT trial was a cluster randomized controlled trial conducted from
2010 to 2013 in Belgium and Canada, comparing early combined
immunosuppression (with a TNF antagonist plus antimetabolite) to conventional
management in patients with CD. After 12 months, the researchers found no
statistically significant difference in remission rates and adverse-medication
reaction occurrences between the early combined immunosuppression cohort
and the conventional therapy cohort (adjusted difference in remission rates: 2.5%
[p=0.5169]). Early combined immunosuppressive therapy was, however,
associated with lower adverse outcomes such as surgery, hospitalization, and
serious disease complications (HR: 0.73, 95% CI:0.62,0.86).40
In a prospective, interventional, controlled study, researchers administered
either infliximab plus azathioprine or prednisone plus azathioprine to patients
with moderate to severe active CD naïve to treatment. After 30 weeks, the deep
remission rates, time to clinical remission, and clinical remission rates were

9

compared between groups. Of the 38 participants in the infliximab plus
azathioprine group, 44.7% achieved deep remission, compared to 17.9% (out
of 39 patients) in the prednisone plus azathioprine group (p=0.011). The median
time to clinical remission was 6.8 weeks for the infliximab plus azathioprine
group and 14.2 weeks for the prednisone plus azathioprine group (p=0.009).
Additionally, the clinical remission rates in the infliximab plus azathioprine group
were higher than the prednisone plus azathioprine group at 30 weeks (68.4%,
43.6%, respectively, p<0.05).41
A prospective, observational study examined bowel damage in patients with
early CD at high risk for disabling disease receiving either SU, TD, or
accelerated

SU

(AC)

therapy,

which

was

initial

therapy

with

an

immunomodulator. The researchers examined rates of mucosal healing,
described as the absence of ulcerations in patients having ulcerations at
baseline. After 36 months, the rates of mucosal healing were 78.8%, 39.9%,
and 42.2% for the TD, AC, and SU cohorts, respectively (p=0.001). The
researchers also found non-statistically significant differences between the TD,
AC, and SU cohorts at 60 months for surgery-free rates (83.2%, 82.5%, 60.3%,
respectively, p=0.16) and hospitalization-free rates (63.9%, 67.8%, 57.4%,
respectively, p=0.58).42
A real-world analysis of PharMetrics administrative claims data from
January 2000 through January 2009 determined if a TD treatment approach
with an anti-TNF medication was associated with improved clinical outcomes.
The researchers identified three cohorts, a SU cohort consisting of patients
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initiating medication therapy with an aminosalicylate or corticosteroid, an
immunosuppressive therapy cohort consisting of patients initiating medication
therapy with a thiopurine or methotrexate, and a TD cohort consisting of patients
initiating medication therapy with an anti-TNF medication. The researchers
found early treatment with an anti-TNF medication was associated with lower
concomitant use of corticosteroids (p<0.05), lower rates of medication regimen
alterations/discontinuations (p<0.05), and CD-related surgeries (p<0.05)
compared to the SU and immunosuppressive therapy cohorts.43
A systematic review of studies examining the clinical effectiveness of TD
therapy in patients with CD published before July 2017 was conducted by Tsui
et al. The researchers identified 19 studies evaluating early biologic and/or
immunomodulator use. The compiled evidence showed a clinical benefit of early
combined therapy for CD when biologics and immunomodulators were
prescribed together; however, biologic therapy and immunomodulator therapy
separately did not have consistent evidence of efficacy or benefit over SU
therapy. The results of this systematic review showed that while TD therapy
showed promise in achieving remission and reducing complications, additional
research to understand the pathophysiology of CD is required to guide
personalized medication therapy and identify patients who will benefit most from
TD therapy.44
A systematic review and meta-analysis conducted by Ungaro et al.
examined the efficacy and safety of top-down, early biologic therapy strategies
in Crohn’s disease. Studies were included in the analysis if patients were
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initiated on biologic therapy within two years of CD diagnosis in the study or if
early biologic was compared to conventional therapy in the study. The
researchers identified 47 studies, including observational studies , retrospective
cohort studies, and one cost-effectiveness study. The meta-analysis found that
early biologic therapy was associated with higher rates of clinical remission (OR
2.10 [95% CI: 1.69,2.60], n=2763, p<0.00001), lower rates of relapse (OR 0.31
[95% CI: 0.14,0.68], n=596, p=0.003) and higher rates of mucosal healing (OR
2.37 [95% CI: 1.78,3.16], n=994, p<0.00001) compared to SU or late
conventional management. The identified cost-effectiveness study conducted
by Beilman et al. is discussed in the “Cost-Effectiveness and Economic
Analyses” section of this thesis (page 14).45
Cost of Crohn’s Disease
According to an analysis using Optum Research Data for the years 2007 to
2016, the estimated inflation-adjusted mean annual direct healthcare cost for
patients with IBD was $22,987. The patients with CD had a higher average allcause total cost of care compared to patients with UC. The estimated mean
annual healthcare cost for patients without IBD was $6,956. The authors
speculate the increased cost in IBD patients compared to controls may be due
to higher healthcare utilization, out-of-pocket expenditure, and productivity loss
associated with IBD.46
In a Truven Health MarketScan database analysis from 2008 to 2015,
researchers designed a Markov model to estimate the overall lifetime healthcare
costs for patients with CD and UC. The researchers found the lifetime total cost
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for a patient with CD was $622,056, which included outpatient ($273,056),
inpatient ($164,298), pharmacy ($163,722), and emergency department
($20,979) costs. The lifetime healthcare costs varied by age of diagnosis. 35
The medical care financial burden of CD was assessed prospectively and
observationally in a cohort of patients with CD from the natural history registry
of IBD patients at the University of Pittsburgh Medical Center from 2009 to 2013.
The median charge per patient for the 5-year follow-up period was $116,838
(IQR: $45,643 – $240,398). Hospitalizations were associated with 67% of total
charges and anti-TNF therapy accounted for 15.2% of total charges.33
A systematic review of studies examining the cost of CD in Western
industrialized countries found the inflation-adjusted direct medical per-patient
per-year costs for CD was $18,022-18,932 in the United States and €2,8986,960 in European countries. Hospitalizations contributed 53-66% of the direct
medical costs per patient, on average. Indirect costs accounted for 28% of total
costs in the United States and 64-69% in Europe.34
Cost-Effectiveness Economic Analyses of Step-Up and Top-Down Therapy
A study conducted using data from the Italian Healthcare System published
in 2013 examined the cost-effectiveness of initial CD treatment with infliximab
by calculating the incremental cost-utility ratio (ICUR) between SU and TD
cohorts. Utility scores, based on mean Crohn’s Disease Activity Index (CDAI)
scores, were used to calculate quality-adjusted life-years (QALYs). Costs were
determined from the third-party payer (Italian Healthcare System) perspective,
including inpatient, outpatient, follow-up, medication, and surgery costs. The
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model time horizon was five years. The researchers found that TD therapy had
a quality-adjusted life expectancy 0.14 QALYs higher than the SU therapy
cohort (3.90 QALYs, 3.76 QALYs, respectively). Furthermore, the cost of
medication therapy for TD was €14,631 and for SU was €15,404. Therefore, TD
therapy was dominant in the cost-effectiveness analysis because it was
associated with an improvement in quality of life and a cost-saving of €773 over
five years. Sensitivity analysis results maintained the dominance of TD therapy
in varying discount rates, surgery rates, relapse rates, and surgery costs. As the
cost of infliximab increased and the time horizon of the model decreased (less
than 5 years), TD therapy was no longer dominant, but the ICUR calculated was
under €100,000/QALY for all scenarios.36 The willingness to pay thresholds in
Europe ranges from €20,000 to €80,000 per QALY.47 The generalizability of
these results to the United States is limited by differing government regulations
and lower medication prices in Italy.48
Beilman et al. assessed the lifetime cost-effectiveness of early (within 2
years) compared to late (greater than 2 years) anti-TNF therapy initiation in CD.
The disease progression after initiating an anti-TNF therapy was simulated in a
Canadian CD cohort using a Markov model. Costs were derived from the Alberta
Ministry of Health. The researchers found early initiation with infliximab or
adalimumab in CD yielded an additional 0.72 and 0.54 QALYs, respectively,
and a saving of $50,418 and $43,969, respectively, compared to late initiation.
Therefore, the authors concluded early initiation with infliximab or adalimumab
(anti-TNF therapies) within two years of CD diagnosis was associated with
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increased QALYs and cost-saving opportunities compared to initiation after two
years.49 The results of this study may not generalize to the United States, given
the difference in healthcare systems and costs between the United States and
Canada.48
A systematic review of economic evaluations published before March 2017
was conducted to assess the cost-effectiveness of treatment strategies for both
UC and CD. The researchers found biologic therapies (infliximab and
adalimumab) were associated with improved outcomes but were not costeffective for all patients and disease severities in CD. Initial and induction
medication therapy with biologics was cost-effective compared to standard care
for patients with moderate or severe CD but was not cost-effective in CD
refractory to conventional medication therapy and post-surgically induced
remission.37
Real-World Evidence of Step-Up and Top-Down Utilization
Siegel et al. conducted a retrospective, observational study of the Truven
Health MarketScan Commercial and Medicare Database to examine treatment
pathways for adult patients with CD and UC from 2008 to 2016. The researchers
identified both incident and prevalent disease and examined treatment patterns.
Treatment for CD was most commonly initiated with either corticosteroid
monotherapy (42%) or 5-aminosalicylic acid monotherapy (35%). Biologic
therapy was used as initial therapy in less than 5% of CD patients, with
adalimumab monotherapy (0.5%) and infliximab monotherapy (0.3%) as the
most common biologic regimens for initial treatment. Furthermore,19% of
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patients with CD had a treatment pathway including biologics in the follow-up
period (ending in 2016) compared to 81% of patients who did not have exposure
to a biologic during the study.50
Another Truven MarketScan Database analysis was conducted by Yu et
al. to examine the utilization trends, relative market share, and costs of
maintenance medication therapy for IBD patients from 2007 to 2015. Over time,
the number of biologics used in the CD cohort increased from 21.8% in 2007 to
43.8% in 2015. Conversely, the use of immunomodulators and 5-aminosalicylic
acid decreased from 2007 to 2015 (27.2% to 18.0%; 34.1% to 21.6%,
respectively). The average per-member-per-year expenditure for patients with
IBD (CD and UC) taking a biologic was $25,275 in 2007 and $36,051 in 2015.51
Rubin et al. conducted a Market Scan Commercial Claims and
Encounters (CCAE) database analysis to assess continuity of initial therapy
prescribed for CD and UC and associated costs from 2006 to 2010. The
researchers identified patients on suboptimal treatment based on rates of
treatment discontinuation, interruption, upward/downward titration, switching,
and augmentation. In the CD cohort, 47.2% of patients were initiated on therapy
with

5-aminosalicylic

acid,

39.8%

with

corticosteroids,

8.2%

with

immunomodulators, and 4.9% with biologics. The all-cause and IBD-specific
costs associated with suboptimal treatment were higher when compared to
patients with optimal therapy in the CD cohort ($73,367, $32,213,
respectively).52
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Siegel et al., Yu et al., and Rubin et al., examined the utilization of SU
and TD treatment sequences in different settings, and with different objectives.
Siegel et al. reported treatment initiation and follow-up patterns, but did not
examine costs or stratify by year. Yu et al. examined the utilization and costs of
biologics compared to other therapies in IBD, but did not specifically assess
therapy choice among newly diagnosed patients. Rubin et al. examined
treatment initiation patterns in CD and UC, and reported first-year costs
associated with optimal and suboptimal treatment, but did not examine the costs
by treatment initiation pattern. Therefore, we identified a gap in the literature, as
to our knowledge no prior study has determined the first-year healthcare
expenditure in patients newly initiating therapy for CD with either SU or TD
treatment sequences.
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CHAPTER 3

METHODOLOGY

This study analyzed the prescribing trends and associated costs for patients
initiating CD medication therapy. A descriptive analysis compared the
demographic and disease characteristics of patients receiving SU or TD therapy.
Then, a predictive model was executed to identify if SU or TD therapy, among
other variables, was associated with higher direct healthcare costs in CD.
Study Design and Data Source
We conducted a retrospective, cohort analysis of Optum’s de-identified
Clinformatics® Data Mart Database (Optum Inc., Eden Prairie, MN) examining
patients newly diagnosed and initiated on pharmaceutical therapy for CD from
2010 to 2018. Given the resources available for this research, a retrospective
cohort study was the best option to investigate the research questions using
data for patients across the US over eight years. The cohorts were identified
based on treatment sequence (SU or TD), from a population of patients initiated
on medication therapy for CD. Patients were followed for one year after
medication initiation to ascertain cost and healthcare utilization outcomes.
Optum’s de-identified Clinformatics® Data Mart is an administrative health
claims database from a national insurer. The database contains detailed, deidentified, longitudinal administrative claims, including pharmacy, medical,
laboratory, and inpatient data. Optum’s de-identified Clinformatics® Data Mart
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was selected as the data source for this research to accomplish the objective of
examining real-world evidence in a large sample size.
Study Population
The study population consisted of adults newly initiated on medication
therapy for CD. Patients were included in the study population if they had at
least two International Classification of Diseases (ICD) codes for CD based on
the method described by McAuliffe et al. (see Table 2 and Table 3 for ICD
codes).53-58 Patients with CD were identified as having at least two diagnosis
codes for CD in any setting at least 30 days apart within the follow-up period
and having a one-year period prior to index diagnosis without either a CDindicated therapy dispensed or a CD ICD code present. The index diagnosis
date was defined as the first diagnosis code appearing on a patient’s claims
record.
Patients with CD newly initiated on medication therapy were identified using
prescriptions dispensed from claims data. The medication exposure period was
the 60-day period following index diagnosis. Patients with a CD-indicated
medication dispensed during the exposure period without any CD-indicated
medication dispensed in the one-year pre-diagnosis period were considered
newly initiated on pharmaceutical therapy for CD. Each patient was followed for
365 days after the 60-day medication exposure period to determine cost and
healthcare utilization. Please see Figure 1 for a study schematic diagram.
Algorithm to Identify Patients with CD in Claims Data (Inclusion)
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Multiple algorithms to identify CD in administrative claims data have been
described in the literature. A review by Ye et al. describes three algorithms to
identify patients with IBD and CD using claims data and compares the obtained
cohort of each.53 The first algorithm, initially described by Herrinton et al,
identified patients with CD as having at least two CD diagnosis codes within any
30-month period.53,59 The McAuliffe et al. algorithm identified patients with CD
as having at least two CD diagnosis codes at least 30 days apart in any time,
setting, or diagnosis location for the study period. 53,54 Lastly, Rezaie et al.
described an algorithm identifying patients with CD in claims data by having ≥2
hospitalizations, ≥4 physician office visits, or ≥2 ambulatory care visits with a
diagnosis code for CD in a 2-year period.53,60 The positive predictive values
(PPV) of the Herrinton et al. algorithm was 81% and 84% when validated with
different electronic medical health records and corresponding claims data,
respectively.59 The Rezaie et al. algorithm had a PPV of 97.4% when validated
with single-payer health records from one Canadian province. 60 The McAuliffe
et al. algorithm was not validated by chart review but was developed to refine
upon the Herrinton et al. algorithm.53 Ye et al. implemented all three algorithms
on Clinformatics® Data Mart data (CDM; Optum, Eden Prairie, MN, USA) and
compared the cohorts identified by each algorithm. The Herrinton et al.
algorithm yielded a CD cohort size of N=124,899, the McAuliffe et al. algorithm
yielded a CD cohort of size N=108,100, and the Rezaie et al. algorithm yielded
a cohort of N=70,919. Ye et al. concluded that all three algorithms have
strengths and weaknesses in identifying patients with CD, and the choice of
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algorithm should be based on the research question.53 The McAuliffe et al.
algorithm, requiring at least two CD diagnosis codes at least 30 days apart,
features methodology and temporal relationships recommended for identifying
patients with chronic disease in administrative healthcare data.61 The 30-day
separation of diagnosis codes may help to rule out misdiagnoses and
misclassifications associated with assigning multiple diagnoses at initial
presentation.53 Therefore, the McAuliffe et al. algorithm was chosen for this
research.54
Exclusion
Patients were excluded from the identified CD cohort based on age, missing
data, enrollment in the healthcare plan, and comorbidities. Patients less than 18
years of age at the date of index diagnosis were excluded. We also excluded
patients without linked prescriptions dispensed data or who did not have any
CD-indicated medication dispensed in the 60-day exposure period. Furthermore,
patients without full enrollment in the healthcare plan for the 790-day study
period or whose pre-index or follow-up periods fell outside 2010 to 2018 were
excluded. Lastly, we excluded patients who had at least two ICD-codes on
different dates for at least one comorbidity treated with a biologic also indicated
for CD (ankylosing spondylitis, Behçet's disease, hidradenitis, Kawasaki
disease, multiple sclerosis, non-radiographic axial spondyloarthritis, psoriasis,
rheumatoid arthritis, ulcerative colitis, and uveitis; see Table 4 for excluded
comorbidities and ICD codes).62
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SU and TD Cohort Definition
Among the cohort of patients newly initiated on medication therapy for CD,
patients were further classified into the SU or TD cohorts based on the initial
therapy prescribed (see Figure 2 for a visual diagram). The initial prescribed
therapy was determined based on the medications dispensed during the 60-day
exposure period after the diagnosis date. If a patient’s initial dispensed therapy
was an anti-inflammatory medication (aminosalicylate, corticosteroid, or
antimicrobial) within the 60 days following initial diagnosis and without an
immunomodulator/biologic agent, the patient was assigned to the SU cohort.
For steroid and antibiotic medications dispensed in the 60-day exposure period,
we required the days supplied to be greater than or equal to 15 days, to exclude
short-term use for other indications, such as acute illness. A patient with initial
dispensed therapy of an immunomodulator and/or biologic was included in the
TD cohort. If a patient had both an immunomodulator/biologic and long-term
anti-inflammatory medication dispensed in the exposure period, we included
them in the TD cohort (see Table 5 for medications used to categorize the SU
and TD cohorts).
Independent Variables of Interest
Variables

of

interest

included

patient

demographic

and

clinical

characteristics. Demographics included patient age at index diagnosis, sex,
geographic location, payer type, and diagnosis year. Geographic location was
determined by a variable in the data dividing the country into 9 regions: East
North Central, East South Central, Middle Atlantic, Mountain, New England,
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Pacific, South Atlantic, West North Central, and West South Central. Payer type
was subdivided into commercial, Medicare for patients less than 65 years, and
Medicare for patients 65 years or older. The diagnosis year variable was derived
from the date of index diagnosis, and was used to identify trends in SU and TD
utilization by year.
Clinical variables included disease location in the GI tract, comorbidities,
GI-related hospitalizations prior to diagnosis, and CD-related surgical
procedures performed in the 60 days following diagnosis. Disease location was
determined based on the CD ICD codes, which are subdivided into disease of
the small intestine (ICD9/10: 555.0, K50.0), large intestine (ICD9/10: 555.1,
K50.1), small and large intestine (ICD9/10: 555.2 K50.8), and unspecified
(ICD9/10: 555.9, K50.9). If the index diagnosis indicated a location in the
gastrointestinal tract of “unspecified,” we then looked at the diagnoses during
the 60-day exposure period to determine if a disease location was specified by
the subsequent ICD10 codes. Comorbidities were quantified using the
Elixhauser index, which generates a diagnosis-derived score weighting a
patient’s comorbidities.63,64 The Elixhauser index was calculated using all
diagnosis codes present in the pre-diagnosis period. Prior GI-related
hospitalization was coded as a binary variable, and patients with one or more
GI-related hospitalization in the one-year pre-diagnosis period were recorded
as patients with a prior hospitalization. GI-related hospitalizations were defined
as having a discharge diagnosis of colonic conditions including indeterminate
colitis

(ICD9/10:

558.9/K52.3),

noninfective
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gastroenteritis

(ICD9/10:

558.9/K52.9), diverticular disease of the colon (ICD9/10: 562.12/K57.3),
enterocolitis due to Clostridium difficile (ICD9/10: 008.45/A04.7), and
unspecified origin of gastroenteritis and colitis (ICD9/10: 009.1/A09.9), as
described by Stepaniuk et al.65 We also included hospitalizations for
stricture/obstruction (ICD9/10: 560.9/K56.6), fistulas (ICD9/10: 569.81/K63.2),
abscesses (ICD9/10: 569.5/K63.0), and ulcers (ICD9/10: 569.82/K63.3), which
are described as complications of CD, in the GI-related hospitalization
definition.10-14 Lastly, we examined CD-related surgical procedures performed
within the 60 days following the index diagnosis as a binary variable. CD-related
surgical procedures were identified using ICD procedure codes for enterostomy
(including colostomy and ileostomy), small bowel resection, colorectal resection,
local excision of large intestine lesion, and other bowel surgeries, as defined by
Long et al.62
Disease Severity
An IBD severity index that can be used to gauge IBD severity using claims
data was developed and validated in a retrospective cohort study using Optum
Clinformatics, IMS PharMetrics, and Truven MarketScan databases from 2013
to 2017. The researchers developed a logistic regression model to identify
variables predictive of severe CD or UC, defined by frequency of IBD-related
hospitalizations and surgeries (colectomy or bowel resection). The factors
identified as predictive of disease severity in CD were female sex, higher
frequency of comorbidities (measured with the Charlson Comorbidity Index),
renal comorbidities, anemia, weight loss, IV corticosteroid use, prior GI-related
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ED visit and/or hospitalization, intestinal fistula, intestinal stricture, disease
location, and time from diagnosis to first biologic therapy.66 The authors
describe a severity score calculation based on assigned risk indexes for each
variable predictive of severe disease. We were able to create comparable
variables for gender, comorbidity frequency (Elixhauser Index), disease location,
GI-related hospitalizations prior to diagnosis, and CD-related surgical
procedures performed within the 60 days following the index diagnosis. We
looked at these severity variables separately, instead of applying the risk index
factors and deriving a severity score because our data source did not include
all of the relevant variables presented in the validated method described by
Chen et al.66
Cost and Utilization
The cost and utilization variables were calculated in the one-year follow-up
period following the 60-day medication exposure period after the index
diagnosis (Figure 1). Both overall any-cause costs and CD-related costs were
calculated. Overall any-cause costs included healthcare expenditures of any
type, encompassing all pharmacy, outpatient healthcare, laboratory testing,
imaging, and hospitalization/emergency department utilization costs. CDrelated costs were calculated as the sum of prescriptions dispensed for CDindicated therapies as well as medical visits and hospitalizations with a primary
diagnosis of CD in the follow-up period. CD-related costs in the follow-up period
were further split into pharmacy and healthcare costs, with pharmacy including
only medication-related costs, and healthcare costs including outpatient
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healthcare visits, laboratory tests, imaging, and hospitalization/emergency
department utilization in the follow-up period. Costs were inflation adjusted to
the 2017 USD ($) value using the Personal Health Care Expenditure
deflator.67,68
Overall CD-specific utilization was calculated as a sum of healthcare visits,
including

outpatient

appointments,

laboratory

tests,

imaging,

hospitalization/emergency department use with CD as the primary diagnosis,
and prescriptions dispensed for CD-indicated therapies in the follow-up period.
CD-specific utilization was also subdivided into medication and healthcare
utilization, with medication utilization representing the number of total
prescriptions dispensed for any CD-indicated medication, and healthcare
utilization representing the number of healthcare visits in the follow-up period.
Cost Analysis
The objective of the cost analysis was to determine if TD therapy is
associated with higher mean per patient total first-year direct healthcare costs
compared to SU therapy, and to identify predictors of overall direct diseasespecific healthcare costs in newly treated patients with CD. To achieve this
objective, we developed a generalized linear model with the primary
independent variable of treatment sequence (SU or TD). Covariates included
sex, age group, disease location, geographic location, payer, Elixhauser index,
GI-related hospitalizations prior to diagnosis, CD-related surgical procedures
performed within the 60 days following the index diagnosis, and diagnosis year.
The dependent variable was direct first-year CD-specific healthcare costs,
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which represented the overall CD-specific cost minus the costs of CD
medications. We did not include CD medication costs in the cost analysis
because TD therapy is associated with higher costing therapies, and the goal of
our analysis was to examine disease cost, not treatment cost.
Statistical Analysis
A descriptive analysis at the patient-level categorized by treatment
sequence (SU or TD) was conducted for all independent variables. Results were
reported using descriptive statistics and significance was tested using t-tests for
continuous variables and chi-squared tests for categorical variables. Similarly,
the mean CD-specific healthcare costs were reported for each independent
variable. T-test and analysis of variance (ANOVA) were used to assess the
significance of the mean CD-specific healthcare costs in the CD cohort, and
pairwise comparisons were performed for multilevel variables, with significance
assessed at the 5% alpha level.
A generalized linear model with a gamma distribution and log link function
was used to estimate the differences in per-patient average adjusted CDspecific healthcare costs for potential predictor covariates. Skewness and
kurtosis were assessed for the CD-specific healthcare cost distribution, and a
modified Park test was used to determine that a gamma distribution was the
best choice for modeling the CD-specific healthcare cost data. The generalized
linear model was optimized with manual backward elimination, and significance
was assessed using chi squared tests of the difference in Akaike information
criterion (AIC). Non-significant variables were removed from the model to
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enhance fit. The model was considered optimized when all included variables
had either at least one statistically significant strata or were considered clinically
relevant irrespective of significance, and removing additional variables did not
result in a statistically significant decrease in AIC. Beta estimates were
exponentiated to derive adjusted odds ratios, standard errors, and 95%
confidence intervals. The estimates presented represent the percentage
difference in cost for a particular level of a variable when other independent
variables are at their reference level. Results with a p-value less than or equal
to 0.05 were discussed. All statistical analyses were performed using SAS
version 9.4 statistical analysis software (SAS Institute, Cary, NC).
The data obtained from the Optum® ClinformaticsTM database for this study
were stored on URI’s secure server. The study proposal was submitted and
considered exempt by the IRB and Research and Development Committee at
URI (Reference Number 1666706) and appropriate training was completed.

28

CHAPTER 4

FINDINGS

Population & Cohort Results
We identified 183,452 patients with an ICD-diagnosis code for CD among
the over 52 million commercial enrollees in Optum’s de-identified Clinformatics®
Data Mart Database. Of the 183,452 patients, 95,549 had two ICD diagnosis
codes for CD at least 30 days apart. Based on the patient’s age at initial
diagnosis, 4,710 patients were excluded for having an age less than 18 years.
Of the resulting 90,839 adult patients in the cohort, prescription information
indicating a dispensing of a CD-indicated medication was available for 70,408
patients. Next, 31,201 patients were identified as initiating pharmaceutical
therapy, because there was a CD-indicated medication dispensed in the 60-day
exposure period without a dispense in the one-year pre-diagnosis period. Of the
31,201 patients, 3,884 individuals had enrollment for the 790-day study period.
Lastly, 727 patients were excluded for having at least one comorbidity treated
with biologics also indicated for CD. The final cohort of adult patients newly
initiated on medication therapy for CD with full enrollment was 3,157 patients.
The SU cohort consisted of 2,392 patients and the TD cohort consisted of 765
patients. Please see Figure 3 for a population flow diagram.
Descriptive Characteristics
The descriptive characteristics are presented in Table 6. The total cohort
was 53.72% female and the mean age was 46.69 years (SD: 18.86 years).
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Additionally, 1,085 (34.37%) of patients had disease in the small intestine, 719
(22.77%) in the large intestine, 902 (28.57%) in both the small and large
intestine, and 451 (14.29%) in an unspecified location. For payer type, 2,444
patients (77.42%) of the total CD cohort were enrolled in commercial insurance,
112 (3.55%) in Medicare and under 65 years of age, and 601 (19.04%) in
Medicare and 65 years of age or older. Of the total CD cohort, 916 patients
(29.01%) had an Elixhauser index of zero, 1,273 patients (40.32%) had an
Elixhauser index of 1-2, and 968 patients (30.66%) had an Elixhauser index
greater than 3. Furthermore, 278 patients (8.81%) of the total CD cohort had an
GI-related hospitalization in the year prior to the index diagnosis date. Lastly,
1,858 patients (58.85%) had at least one CD-related surgical procedure
performed within 60 days following the index diagnosis.
In the follow-up period, the overall all-cause average per-patient inflationadjusted cost in the study population was $38,887 (SD: $83,818), the average
per-patient CD-specific total cost was $16,830 (SD: $28,305), the average perpatient CD-specific healthcare cost was $6,321 (SD: $19,627), and the average
per-patient CD-specific medication cost was $10,414 (SD: $16,216).
Additionally, in the follow-up period, the average CD-specific healthcare
utilization was 8.34 visits (SD: 11.27) per patient, and the average CD-specific
medication utilization was 8.08 prescriptions dispensed (SD: 6.84) per patient.
The cost and utilization results are presented in Table 7.
The SU cohort consisted of a slightly larger proportion of females than the
TD cohort (55.02%, 49.67%, respectively, p=0.0099). The mean age in the SU
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cohort was 48.92 years (SD: 18.90), which was higher than the mean age of
39.72 years (16.69) in the TD cohort (p<0.0001). When age was divided into
four age groups, a larger proportion of patients in the SU cohort were
categorized in the older age groups, and a larger proportion of patients in the
TD cohort were in the younger age groups (chi-squared p<0.0001, see Table 6
for proportions and Figure 4 for a visual of the age distribution in the SU and TD
cohorts).
The unadjusted results also indicated that the SU cohort had a larger
percentage of patients with disease in either the small or large intestine and the
TD cohort had a larger percentage of patients with disease located in both the
small and large intestine, or an unspecified location (chi-squared p<0.0001). For
geographic location, a larger proportion of patients in the SU cohort were
located in either the Middle Atlantic, Mountain, Pacific, or South Atlantic region,
a larger proportion of patients in the TD cohort located in the East North Central
and West North Central regions, and a similar proportion of patients between
the SU and TD cohorts located in the East South Central, New England, and
West South Central regions (chi-squared p<0.0001). Furthermore, more
patients in the TD cohort had commercial insurance, and more patients in the
SU cohort had Medicare (for patients both <65 and ≥65 years of age; chisquared p<0.0001). The mean Elixhauser index was higher in the SU cohort
compared to the TD cohort (2.2 [SD: 2.50], 1.65 [2.11], respectively, p<0.0001).
When categorized by an Elixhauser index of 0, 1-2, or >3, the TD cohort had a
larger percentage of patients with a score of 0 (32.68%, SU: 27.84%) or 1-2
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(45.62%, 38.63%), while the SU cohort had a larger percentage of patients with
scores >3 (33.53%, TD: 21.70%, chi-squared p<0.0001). We also found that the
frequency of TD utilization increased over time (chi-squared p<0.0001, see
Table 6 for proportions and Figure 5 for a visual of SU and TD utilization over
time).
The bivariate average overall all-cause cost, CD-specific total cost, CDspecific healthcare costs, and CD-specific medication costs over the follow-up
period were significantly different between the SU and TD cohort, with TD
having higher costs in all categories (p<0.0001). Similarly, average utilization
over the one-year follow-up period in the TD cohort compared to SU cohort was
significantly higher (p<0.0001) in the for CD-specific healthcare (TD: 14.35, SU:
6.42 visits) and medication utilization (TD: 11.53, SU: 6.97 prescriptions
dispensed). See Figure 6 for a visual of cost and utilization by CD, SU, and TD
cohorts.
The mean CD-specific healthcare costs are reported for each independent
variable in Table 8. Since the distribution of CD-specific healthcare costs was
right skewed (skew: 4.43) with a platykurtic distribution (kurtosis: 28.05), the
standard deviations are larger than the means. The mean CD-specific
healthcare cost was not significantly different between females and males
(p=0.8557), geographic locations (p=0.9542), Elixhauser indexes (p=0.5287),
diagnosis year (p=0.0741, see Figure 7) and between those who had and did
not have a CD-related surgical procedure performed within the 60 days
following index diagnosis(p=0.0603) in the CD-cohort (study population). The
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average

follow-up

disease-specific

healthcare

costs

were

statistically

significantly different between commercial, Medicare and under 65 years of age,
and Medicare and 65 years of age or older (p=0.0006), with commercial having
a higher mean CD-specific healthcare cost (commercial: $7,021, Medicare age
<65: $2,188 Medicare age≥65: $4,246, based on Tukey follow-up test). The CDspecific healthcare cost was also significantly different between the age groups
(p<0.0001), and based on a Tukey follow-up test, the youngest age groups
(aged 18-29 years) had a significantly higher mean cost. The mean CD-specific
healthcare cost was also significantly different by disease location, with all
pairwise comparisons being significant except the large intestine and unspecific
location comparison (small intestine: $7,071 large intestine:$3,450, both small
and large intestine: $10,050, unspecified location: $1,637). Lastly, patients
having a GI-related hospitalization prior to diagnosis had a significantly higher
mean CD-specific healthcare cost compared to patients not hospitalized prior to
diagnosis ($10,143, $5,952, respectively).
Linear Regression Findings
We conducted a generalized linear model to observe predictors of CDspecific healthcare cost in patients with CD. The geographic location variable
was statistically nonsignificant and removed to enhance the fit of the model.
Though the gender, Elixhauser index, and CD-related surgical procedure
variables were non-significant, eliminating these variables from the model did
not produce a statistically significantly better fitting model, based on a chisquared test, and these variables were retained due to their clinical relevance.
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The results of the model with geographic location removed are presented in
Table 9, and the full model results are presented in Table 10.
In the optimized generalized linear model with a gamma distribution and log
link, treatment strategy, age group, disease location, GI-related hospitalization
prior to diagnosis, payer, and diagnosis year were significant predictors of firstyear adjusted average per-patient CD-specific direct healthcare cost. CD
treatment initiated with TD therapy had a first-year adjusted average per-patient
CD-specific direct healthcare cost that was 149.78% ($1,230.26) higher than
initiation with SU therapy. Furthermore, compared to patients older than 65
years, those aged 18-29, 30-44, and 45-64 years had an increased first-year
adjusted average per-patient CD-specific direct healthcare cost of 269.91%
($2,217.05), 137.76% ($1,131.57), 85.63% ($703.38), respectively. CD located
in the small intestine or both the small and large intestine had a 99.43%
($816.72) or 207.04% ($1,700.59) higher first-year adjusted average per-patient
CD-specific direct healthcare cost, respectively, than CD located in the large
intestine. Conversely, CD of unspecified location was associated with a 57.38%
($471.30) lower first-year adjusted average per-patient CD-specific direct
healthcare cost than CD located in the large intestine. Patients with a GI-related
hospitalization in the pre-diagnosis period had a 179.69% ($1,475.93) higher
first-year adjusted average per-patient CD-specific direct healthcare cost than
those not hospitalized in the pre-diagnosis period. Patients aged less than 65
years using Medicare had a first-year adjusted average per-patient CD-specific
direct healthcare cost of 58.95% ($484.22) lower than patients using
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commercial insurance. Lastly, compared to 2011, the first-year adjusted
average per-patient CD-specific direct healthcare cost was 36.48% ($299.64),
73.93% ($607.28), and 37.85% ($310.90) higher in 2013, 2014, and 2016,
respectively.

.
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CHAPTER 5

DISCUSSION AND CONCLUSION

This study attempted to fill a gap in the literature by examining SU and TD
therapy utilization and short-term expenditures in patients newly initiated on
medication therapy for CD in a real-world setting using a large administrative
claims database. We described trends overtime and stratified by demographic
and clinical variables to examine SU and TD therapy usage patterns in an
observational data setting. We also used a generalized linear model to
illuminate factors predictive of higher first-year healthcare expenditures in
patients newly initiated with medication therapy for CD. We found that a larger
proportion of patients were initiated on SU therapy compared to TD therapy
during the 2010 to 2018 study period, but over time, the proportion of patients
initiated on TD therapy increased. In our study the TD cohort also had a lower
mean age, higher frequency of commercial insurance, and higher proportion of
disease manifesting in both the small and large intestine. Our disease-specific
healthcare cost model showed that TD therapy was associated with a higher
mean cost compared to SU therapy. Other factors we identified as predictive of
a higher CD-specific healthcare cost were age, disease location, and having a
GI-related hospitalization prior to diagnosis. These findings can inform payer
decisions, pharmaceutical policies, and guideline recommendations.
Our analysis revealed that in a population of patients newly diagnosed with
CD, SU was more commonly utilized than TD (75.8%, 24.2% respectively). The
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frequency of TD therapy utilization among the patients initiated on medication
therapy for CD increased over time from 17% in 2011 to 31% in 2018. (Figure
5). This trend may be attributed to the increased availability of and
provider/patient familiarity with biologic agents during the study timeframe. In
2014, vedolizumab was FDA approved for the treatment of UC and CD. 69,70
Additionally, in 2014 the indications of adalimumab were expanded to include
CD.69,71 In 2016, the indications for ustekinumab were expanded to include
CD.69,72 Biosimilars for infliximab were also approved during the study period,
with Inflectra in 2016, and Renflexis and Ixifi in 2017. 69,73-75 The approval of
these products, in addition to publications of research examining therapy
sequencing, may have influenced the increased utilization of TD therapy in later
years of our study. Additionally, we noted a spike in CD-specific healthcare
expenditure in 2014 (Figure 7), which may be related to the adalimumab and
vedolizumab approval in 2014 and/or the Affordable Care Act health insurance
exchanges opening during that year.69-72,76
Overall all-cause cost, CD-specific total cost, CD-specific healthcare cost,
and CD-specific medication costs were higher in the TD cohort compared to the
SU cohort. The predictive analysis showed that TD therapy was associated with
an increased average per-patient CD-specific healthcare cost in the one-year
follow-up period compared to SU therapy (OR: 2.50, 95%CI: [2.12,2.95]). In the
short term, medication prices and adverse events associated with TD therapy
can result in increased prescriber visits, hospitalizations, and cost.22-25,29,30 Our
analysis confirmed that the expenditure and frequency of healthcare utilization
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was higher in the TD compared to the SU cohort. The TD cohort had a higher
average cost for CD-indicated medications dispensed and a higher average
disease-specific healthcare utilization in the follow-up period.
Ascertaining disease severity from claims data is challenging due to limited
patient-specific symptom and pathophysiology data. In our model, diagnosis
location, GI-related hospitalizations prior to diagnosis, and CD-related surgical
procedures performed within the 60 days following the index diagnosis were
indicators of disease severity. Disease location, determined by ICD codes, had
a significant relationship with treatment strategy (chi-squared p<0.0001), with
the SU cohort having a larger percentage of patients with disease in either the
small or large intestine and the TD cohort having a larger percentage of patients
with disease located in the small and large intestine. CD located in the small
intestine or in both the small and large intestine was associated with a higher
cost than disease in the large intestine (OR: 1.99 [1.66,2.40], 3.07 [2.53,3.72],
respectively). In a retrospective analysis examining factors associated with
severe disease in claims data, disease located in the ileum, ileum/colon, and
unspecified were associated with increased severity of disease, characterized
by increased hospitalizations and surgeries, compared to disease in the colon.66
Our results emulate this finding by suggesting that disease location in the ileum
and ileum/colon were associated with a higher first-year healthcare cost, with
disease in the colon as the reference.
Furthermore, though a similar frequency of patients had a GI-related
hospitalization in the pre-CD diagnosis period in the SU cohort (9.03%) and TD
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cohort (8.10%), patients who had a GI-related hospitalization prior to CDdiagnosis had a higher average healthcare cost than those without a GI-related
hospitalization prior to CD diagnosis (OR: 2.80 [2.18,3.63]). Therefore, the
hospitalization prior to diagnosis could be indicative of severe disease or
inflammation activity prior to diagnosis. A prior study examining severity of CD
suggest patients with a GI-related hospitalization prior to IBD diagnosis have an
increased risk of hospitalizations and surgeries after diagnosis, which could be
an indicator for severe CD.66 We also observed that 61.43% of the TD cohort
and 58.03% of the SU cohort had at least one CD-related surgical procedure
performed within the 60 days following index diagnosis. These procedures are
typically reserved for severe disease.10-14 However, the healthcare costs for
patients having procedures within 60-days of diagnosis were not significantly
higher than those who did not have a procedure in our linear model (OR: 0.91
[0.78,1.05]).
Our analysis showed that TD treatment was more frequent as an initial
therapy sequence for CD in the younger age groups, while SU treatment was
more frequently initiated in the older age groups (Figure 4). These results are
similar to an analysis of the Winnipeg Regional Health Authority (WRHA), a
Canadian health region hospitalization discharge database examining the
clinical course, presentation, and management of older and younger patients
hospitalized with IBD. The researchers found that older patients were
prescribed aminosalicylates more often (61%, 43%, respectively, p=0.04) and
biologics less often (6%, 21%; respectively, p=0.016) than younger patients.
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The researchers also conducted a logistic regression analysis to identify
predictors of immunomodulator or biologic use, and found that the only
significant predictor was age (OR of young compared to age 65 or older: 2.47
[95% CI: 1.21, 5.05]).65
In our cost predictive model, younger age groups were associated with
higher average per-patient CD-specific healthcare cost in the follow-up period;
the 18-29 aged group had the highest odds of increased adjusted CD-specific
healthcare cost, followed by the 30-44 aged group and the 45-65 aged group
(OR: 3.70 [2.22,5.84], 2.38 [1.43,3.73], 1.86 [1.13,2.89], respectively). This
finding aligns with the findings of a study examining risk factors that may predict
TD therapy use among 207 patients with CD in China. The authors conducted
two logistic regression models, varying the independent variables of site of
diagnosis and steroid requirements for flare/exacerbation, to predict which risk
factors were associated with developing a disabling disease. Based on the
logistic model that most matches the ICD9/10 codes for site of diagnosis, the
authors found age at diagnosis below 40 years was a significant predictor of
developing disabling CD with a 5-year timeframe. The non-significant risk
factors were site of disease at diagnosis, systemic manifestations at diagnosis,
perianal disease at diagnosis, steroid requirements for first flare, sex, previous
appendectomy, and smoking status at diagnosis.77 While the authors did not
report findings related to expenditure, their results may be similar to the findings
of our study, assuming severe disease leads to higher healthcare expenditure.
Aside from the relationship between age and severity of disease established by
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previous

studies,

we

question

if

disease

presentation,

medication

burden/therapy interactions, insurance, and expected life expectancy might be
influencing the age effect we observed with a higher frequency of TD use and a
higher average per-patient CD-specific healthcare cost in younger patients.
Our study also showed that the TD cohort had a larger proportion of
commercial insurance utilization than the SU cohort, and patients with
commercial insurance had a higher CD-specific healthcare cost than patients
with Medicare (both <65 and ≥65 years of age). This finding may be related to
commercial and Medicare coverage policies for biologics. While we were unable
to examine past coverage policies for the CD-indicated biologics, we examined
the current (2021) commercial coverage policies for certolizumab pegol,
infliximab, natalizumab, ustekinumab, and vedolizumab; we were unable to
locate publicly available policies for adalimumab. Certolizumab pegol and
infliximab coverage required a history of failing medication therapy with
corticosteroids, 6-mercaptopurine, azathioprine, and/or methotrexate.78,79
Natalizumab required a history of inadequate response to both conventional
therapies (SU therapies) and inadequate response to TNF-alpha inhibitors for
coverage.80 Ustekinumab and vedolizumab did not have a requirement of failing
a non-biologic therapy prior to initiating pharmaceutical therapy for CD. 81,82
Based on a current medication formulary, the biologic agents indicated for CD
were tier 2 or greater, while the small molecule medications, including
aminosalicylates and immunomodulators were tier 1.83 Therefore, payer type
may influence the ease and affordability of obtaining SU or TD medication.
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Furthermore, our finding of a higher frequency of commercial insurance in the
TD cohort may be influenced by the difference in out-of-pocket costs between
commercial and Medicare insurance. Medicare Part D has a 25% cost sharing
for most medications and is associated with coverage gaps (the doughnut hole)
requiring even higher cost sharing. The cost sharing and coverage gaps vary
between commercial payer plans but tend to be favorable compared to
Medicare. Patients having to pay large out-of-pocket co-payments for their
medications may request the SU therapies due to affordability.
As more therapies being developed and approved for CD fall into the
biologic, specialty, and/or high-cost categories, the prescription spending for
payers and the healthcare system will likely increase for CD. 32 Insurance
companies, managed care organizations, and payers use methods, such as
prior authorizations, formularies, quantity limits, and co-payments, to control
prescription costs and utilization for certain, usually expensive, medications. 32
Payers face the challenge of balancing potential long-term cost-effectiveness
with short-term high prescription medication costs. Factors such as the severity
of disease and the potential length of time a patient is on the higher-costing
medication therapies are important for payers to consider when judging the
value of higher-cost TD therapies compared to SU therapies in patients initiating
treatment for CD. Ultimately, SU and TD therapy options both have positives
and negatives that must be weighted based on patient-specific factors to
determine which treatment plan provides patients the best efficacy and
minimizes exposure to unnecessary risk.
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The patient and disease characteristics we identified as significant in SU
and TD utilization and expenditure can inform future studies, payer decisions,
and pharmaceutical therapy recommendations to identify patients who may
receive TD therapy or have a higher expenditure. While the benefits of TD
therapy have been studied and postulated in a clinical trial setting 38-45, limited
evidence exists that examines the use and short-term costs associated with SU
and TD therapy in a real-world setting. Our research illuminates real-world
trends in SU and TD therapy use and examines the characteristics of patients
receiving either SU and TD therapy in the United States. Further research is
needed to determine the long-term overall healthcare costs associated with SU
and TD treatment strategies in a real-world setting.
The design and data available for this study introduced inherent limitations
worth acknowledging. The data source used for this analysis does not have
specific information describing the severity of the disease, which is a factor that
influences the choice of initial medication therapy. Our analysis did include
disease location, GI-related hospitalizations prior to diagnosis, and CD-related
surgical procedures performed within the 60 days following the index diagnosis ,
which can be indicators of increased disease severity. However, we were
unable to account for symptom burden, mucosal tissue damage, and other
indicators of disease severity.10-14,66 Additionally, while pharmacy claims data
provides detailed information on medication names, doses, and dispense dates,
pharmacy claims data only captures medications charged to the health plan.
Thus, medications distributed through specialty channels that bypass
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community pharmacies may not have been recorded in the database used for
our analysis. Furthermore, we only assessed initial therapy dispensed in the 60
days after index diagnosis and did not account for therapy switching or
adherence during the follow-up period. Prescriber bias may be present in this
study. Each prescriber may have a different preference for TD or SU therapy,
which will influence prescribing practices. Misdiagnosis and reporting bias may
also be present in this study as a result of relying on ICD coding to determine
CD diagnosis and index diagnosis date. Lastly, we only address short-term
costs among newly treated patients with CD in this study, therefore the results
may not be generalizable to longer-term costs (over one year) or patients with
prevalent disease.
We examined the utilization and expenditure of SU and TD treatment
strategies in patients initiating medication therapy for CD in a real-world setting.
We found the proportion of TD therapy utilization increased each year of our
study period. Furthermore, TD was associated with a higher overall and CDspecific cost in a one-year period following the CD diagnosis and medication
exposure. Our predictive model showed that treatment strategy, age group,
disease location, GI-related hospitalization prior to diagnosis, payer, and
diagnosis year were significant predictors of CD direct healthcare costs. These
findings can be used to inform pharmaceutical policy and provide a basis for
further research to understand the real-world outcomes associated with SU and
TD therapy.
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APPENDIX 1: TABLES
Table 1: Medications Indicated for Crohn’s Disease10-14

Aminosalicylates

Medication
Class

Medication Name

Mechanism of Action

Balsalazide (ColazalTM)

Anti-inflammatory,
5-Aminosalicylate (5-ASA) precursor

Mesalamine
(Oral = PentasaTM, AsacolTM)
(Rectal = RowasaTM)

Anti-inflammatory,
5-Aminosalicylate (5-ASA) precursor

Olsalazine (DipentumTM)

Budesonide

Glucocorticoid

Betamethasone

Glucocorticoid

Cortisone

Glucocorticoid/Mineralocorticoid

Dexamethasone

Glucocorticoid

Hydrocortisone

Glucocorticoid

Methylprednisolone

Glucocorticoid

Prednisone

Glucocorticoid

Prednisolone

Glucocorticoid

Triamcinolone

Glucocorticoid

Anti-microbial

Antibiotic
Nitroimidazole Agent
Antibiotic
Fluoroquinolone Agent

Metronidazole (FlagylTM)

Immunomodulators

Corticosteroids

Sulfasalazine

Anti-inflammatory,
5-Aminosalicylate (5-ASA) precursor
Anti-inflammatory,
5-Aminosalicylate (5-ASA) precursor

Azathioprine

Purine Synthesis Inhibitor

Cyclosporine

Calcineurin Inhibitor

Mercaptopurine (6-MP)

Purine Analog, Antimetabolite

Methotrexate

Folic Acid Analog

Tacrolimus

Calcineurin Inhibitor

Ciprofloxacin (CiproTM)

Adalimumab (HumiraTM)

Biologic

Certolizumab pegol (CimziaTM)
Infliximab (RemicadeTM)

Tumor Necrosis Factor (TNF)-α
Inhibitor
Tumor Necrosis Factor (TNF)-α
Inhibitor
Tumor Necrosis Factor (TNF)-α
Inhibitor

Natalizumab (TysabriTM)

Adhesion Molecule Inhibitors

(StelaraTM)

Interleukin-23 (IL-23) Inhibitor

Vedolizumab (EntyvioTM)

Adhesion Molecule Inhibitors

Ustekinumab
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Table 2: Crohn’s Disease International Classification of Disease (ICD) 10/9
Codes55-58
ICD-10:
K50.xxx

ICD-9:
555.xx

K50.0: Crohn’s disease of small intestine

555.0: Regional enteritis of small intestine

K50.1: Crohn’s disease of large intestine

555.1: Regional colitis of large intestine

K50.8: Crohn’s disease of small and
large intestine

555.2: Regional enteritis of small intestine with large intestine

K50.9: Crohn’s disease, unspecified

555.9: Regional enteritis of unspecified
site

ICD = International Classification of Diseases
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Table 3: International Classification of Disease (ICD)-10 Codes and
Comparable ICD-9 Codes with Descriptions for Crohn’s Disease55-58
ICD10
K5000
K50011
K50012
K50013
K50014
K50018
K50019
K5010
K50111
K50112
K50113
K50114
K50118
K50119
K5080
K50811
K50812
K50813
K50814
K50818
K50819
K5090
K50911
K50912
K50913
K50914
K50918
K50919

ICD10 Code Description
Crohn's disease of small intestine without
complications
Crohn's disease of small intestine with
rectal bleeding
Crohn's disease of small intestine with
intestinal obstruction
Crohn's disease of small intestine with
fistula
Crohn's disease of small intestine with
abscess
Crohn's disease of small intestine with
other complication
Crohn's disease of small intestine with
unspecified complications
Crohn's disease of large intestine without
complications
Crohn's disease of large intestine with
rectal bleeding
Crohn's disease of large intestine with
intestinal obstruction
Crohn's disease of large intestine with
fistula
Crohn's disease of large intestine with
abscess
Crohn's disease of large intestine with
other complication
Crohn's disease of large intestine with
unspecified complications
Crohn's disease of both small and large
intestine without complications
Crohn's disease of both small and large
intestine with rectal bleeding
Crohn's disease of both small and large
intestine with intestinal obstruction
Crohn's disease of both small and large
intestine with fistula
Crohn's disease of both small and large
intestine with abscess
Crohn's disease of both small and large
intestine with other complication
Crohn's disease of both small and large
intestine with unspecified complications
Crohn's disease, unspecified, without
complications
Crohn's disease, unspecified, with rectal
bleeding
Crohn's disease, unspecified, with
intestinal obstruction

ICD9

Crohn's disease, unspecified, with fistula

5559

Crohn's disease, unspecified, with
abscess
Crohn's disease, unspecified, with other
complication
Crohn's disease, unspecified, with
unspecified complications
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5550
5550
5550
5550
5550
5550
5550
5551
5551
5551
5551
5551
5551
5551
5552
5552
5552
5552
5552
5552
5552
5559
5559
5559

5559
5559
5559

ICD9 Code Description
Regional enteritis of small
intestine
Regional enteritis of small
intestine
Regional enteritis of small
intestine
Regional enteritis of small
intestine
Regional enteritis of small
intestine
Regional enteritis of small
intestine
Regional enteritis of small
intestine
Regional enteritis of large
intestine
Regional enteritis of large
intestine
Regional enteritis of large
intestine
Regional enteritis of large
intestine
Regional enteritis of large
intestine
Regional enteritis of large
intestine
Regional enteritis of large
intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of small
intestine with large intestine
Regional enteritis of unspecified
site
Regional enteritis of unspecified
site
Regional enteritis of unspecified
site
Regional enteritis of unspecified
site
Regional enteritis of unspecified
site
Regional enteritis of unspecified
site
Regional enteritis of unspecified
site

Table 4: Comorbidities Treated with Biologics that are Indicated for Crohn’s
Disease and Associated International Classification of Disease (ICD) 10/9
Codes62,84-86
Comorbidity
Ankylosing
Spondylitis

Behçet's Disease

Hidradenitis
Suppurativa
Kawasaki Disease
Multiple Sclerosis
Non-Radiographic
Axial
Spondyloarthritis
Psoriasis
Psoriatic Arthritis

Juvenile Idiopathic
Arthritis,
Polyarticular
Juvenile Idiopathic
Arthritis,
Rheumatoid Arthritis

ICD10
M45.0, M45.1, M45.2, M45.3, M45.4, M45.5, M45.6,
M45.7, M45.8, M45.9

ICD9
720.0

M35.2

711.20, 711.21,
711.22, 711.23,
711.24, 711.25,
711.26, 711.27,
711.28, 711.29,
136.1

L73.2

705.83

M30.3
G35

446.1
340

M46.80, M46.81, M46.82, M46.83, M46.84, M46.85,
M46.86, M46.87, M46.88, M46.89

720.89

L40.0, L40.1, L402, L403, L404, L4050, L4051, L4052,
L4053, L4054, L4059, L408, L409
M05.20, M05.211, M05.212, M05.219, M05.221,
M05.222, M05.229, M05.231, M05.232, M05.239,
M05.241, M05.242, M05.249, M05.251, M05.252,
M05.259, M05.261, M05.262, M05.269, M05.271,
M05.272, M05.279, M05.29, M05.30, M05.311,
M05.312, M05.319, M05.321, M05.322, M05.329,
M05.331, M05.332, M05.339, M05.341, M05.342,
M05.349, M05.351, M05.352, M05.359, M05.361,
M05.362, M05.369, M05.371, M05.372, M05.379,
M05.39, M05.40, M05.411, M05.412, M05.419,
M05.421, M05.422, M05.429, M05.431, M05.432,
M05.439, M05.441, M05.442, M05.449, M05.451,
M05.452, M05.459, M05.461, M05.462, M05.469,
M05.471, M05.472, M05.479, M05.49, M05.50,
M05.511, M05.512, M05.519, M05.521, M05.522,
M05.529, M05.531, M05.532, M05.539, M05.541,
M05.542, M05.549, M05.551, M05.552, M05.559,
M05.561, M05.562, M05.569, M05.571, M05.572,
M05.579, M05.59, M05.60, M05.611, M05.612,
M05.619, M05.621, M05.622, M05.629, M05.631,
M05.632, M05.639, M05.641, M05.642, M05.649,
M05.651, M05.652, M05.659, M05.661, M05.662,
M05.669, M05.671, M05.672, M05.679, M05.69,
M05.70, M05.711, M05.712, M05.719, M05.721,
M05.722, M05.729, M05.731, M05.732, M05.739,
M05.741, M05.742, M05.749, M05.751, M05.752,
M05.759, M05.761, M05.762, M05.769, M05.771,
M05.772, M05.779, M05.79, M05.7A, M05.80, M05.811,
M05.812, M05.819, M05.821, M05.822, M05.829,
M05.831, M05.832, M05.839, M05.841, M05.842,
M05.849, M05.851, M05.852, M05.859, M05.861,
M05.862, M05.869, M05.871, M05.872, M05.879,
M05.89, M05.8A, M05.9, M06.00, M06.011, M06.012,
M06.019, M06.021, M06.022, M06.029, M06.031,
M06.032, M06.039, M06.041, M06.042, M06.049,
M06.051, M06.052, M06.059, M06.061, M06.062,
M06.069, M06.071, M06.072, M06.079, M06.08,
M06.09, M06.0A, M06.1, M06.20, M06.211, M06.212,
M06.219, M06.221, M06.222, M06.229, M06.231,
M06.232, M06.239, M06.241, M06.242, M06.249,
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696.0, 696.1

714.0, 714.2,
714.30, 714.31,
714.32, 714.33,
714.9

Table 4 Continued
Comorbidity

Juvenile Idiopathic
Arthritis,
Polyarticular
Juvenile Idiopathic
Arthritis,
Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

ICD10
M06.251, M06.252, M06.259, M06.261, M06.262,
M06.269, M06.271, M06.272, M06.279, M06.28,
M06.29, M06.30, M06.311, M06.312, M06.319,
M06.321, M06.322, M06.329, M06.331, M06.332,
M06.339, M06.341, M06.342, M06.349, M06.351,
M06.352, M06.359, M06.361, M06.362, M06.369,
M06.371, M06.372, M06.379, M06.38, M06.39, M06.4,
M06.80, M06.811, M06.812, M06.819, M06.821,
M06.822, M06.829, M06.831, M06.832, M06.839,
M06.841, M06.842, M06.849, M06.851, M06.852,
M06.859, M06.861, M06.862, M06.869, M06.871,
M06.872, M06.879, M06.88, M06.89, M06.8A, M06.9,
M08.00, M08.011, M08.012, M08.019, M08.021,
M08.022, M08.029, M08.031, M08.032, M08.039,
M08.041, M08.042, M08.049, M08.051, M08.052,
M08.059, M08.061, M08.062, M08.069, M08.071,
M08.072, M08.079, M08.08, M08.09, M08.0A, M08.1,
M08.20, M08.211, M08.212, M08.219, M08.221,
M08.222, M08.229, M08.231, M08.232, M08.239,
M08.241, M08.242, M08.249, M08.251, M08.252,
M08.259, M08.261, M08.262, M08.269, M08.271,
M08.272, M08.279, M08.28, M08.29, M08.2A, M08.3,
M08.40, M08.411, M08.412, M08.419, M08.421,
M08.422, M08.429, M08.431, M08.432, M08.439,
M08.441, M08.442, M08.449, M08.451, M08.452,
M08.459, M08.461, M08.462, M08.469, M08.471,
M08.472, M08.479, M08.48, M08.4A, M08.80, M08.811,
M08.812, M08.819, M08.821, M08.822, M08.829,
M08.831, M08.832, M08.839, M08.841, M08.842,
M08.849, M08.851, M08.852, M08.859, M08.861,
M08.862, M08.869, M08.871, M08.872, M08.879,
M08.88, M08.89, M08.90, M08.911, M08.912, M08.919,
M08.921, M08.922, M08.929, M08.931, M08.932,
M08.939, M08.941, M08.942, M08.949, M08.951,
M08.952, M08.959, M08.961, M08.962, M08.969,
M08.971, M08.972, M08.979, M08.98, M08.99, M08.9A
K51.00, K51.011, K51.012, K51.013, K51.014, K51.018,
K51.019, K51.20, K51.211, K51.212, K51.213, K51.214,
K51.218, K51.219, K51.30 , K51.311, K51.312, K51.313,
K51.314, K51.318, K51.319, K51.40, K51.411, K51.412,
K51.413, K51.414, K51.418, K51.419, K51.50 , K51.511,
K51.512, K51.513, K51.514, K51.518, K51.519, K51.80 ,
K51.811, K51.812, K51.813, K51.814, K51.818, K51.819,
K51.90 , K51.911, K51.912, K51.913, K51.914, K51.918,
K51.919
H20.9
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ICD9

714.0, 714.2,
714.30, 714.31,
714.32, 714.33,
714.9

556.0, 556.1,
556.2, 556.3,
556.4, 556.5,
556.6, 556.8,
556.9

364.11, 364.3

Table 5: Crohn’s Disease-Indicated Medications Used to Categorize Step-Up
and Top-Down Cohorts1,11-18
SU Medications
Aminosalicylates

TD Medications
Immunomodulators

Balsalazide
Mesalamine
Olsalazine
Sulfasalazine

Azathioprine
Cyclosporine
Mercaptopurine
Methotrexate
Tacrolimus

Corticosteroids

Biologics

Budesonide
Betamethasone
Cortisone
Dexamethasone
Hydrocortisone
Methylprednisolone
Prednisone
Prednisolone
Triamcinolone

Adalimumab
Certolizumab pegol
Infliximab
Natalizumab
Ustekinumab
Vedolizumab

Antimicrobial
Ciprofloxacin
Metronidazole
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Table 6: Crohn’s Disease, Step-Up, and Top-Down Cohort Baseline
Characteristics
CD Cohort
(Study Population)

SU Cohort

TD Cohort

n (%)
3,157
2,392 (75.77)
765 (24.23)
Sex
Female (n, %)
1,696 (53.72)
1,316 (55.02)
380 (49.67)
Age at Diagnosis
Age, Years (mean, SD)
46.69 (18.86)
48.92 (18.90)
39.72 (16.96)
Age: 18-29 years (n, %)
737 (23.34)
460 (19.23)
277 (36.21)
Age: 30-44 years
797 (25.25)
585 (24.46)
212 (27.71)
Age: 45-64 years
948 (30.03)
755 (31.56)
193 (25.23)
Age: ≥ 65 years
675 (21.38)
592 (24.75)
83 (10.85)
Disease Location (ICD 9/10 Code) at Diagnosis
Small Intestine (555.0, K50.0) (n,%)
1,085 (34.37)
832 (34.78)
253 (33.07)
Large Intestine (555.1, K50.1)
719 (22.77)
585 (24.46)
134 (17.52)
Small and Large Intestine (555.2 K50.8)
902 (28.57)
601 (25.13)
301 (39.35)
Unspecified (555.9, K50.9)
451 (14.29)
374 (15.64)
77 (10.07)
Geographic Location
East North Central (n, %)
567 (17.96)
403 (16.85)
164 (21.44)
East South Central
96 (3.04)
72 (3.01)
24 (3.14)
Middle Atlantic
218 (6.91)
173 (7.23)
45 (5.88)
Mountain
287 (9.09)
227 (9.49)
60 (7.84)
New England
145 (4.59)
114 (4.77)
31 (4.05)
Pacific
339 (10.74)
266 (11.12)
73 (9.54)
South Atlantic
782 (24.77)
624 (26.09)
158 (20.65)
West North Central
352 (11.15)
231 (9.66)
121 (15.82)
West South Central
371 (11.75)
282 (11.79)
89 (11.63)
Payer
Commercial (n, %)
2,444 (77.42)
1,770 (74.00)
674 (88.10)
Medicare, Age < 65 (n, %)
112 (3.55)
91 (3.80)
21 (2.75)
Medicare, Age ≥ 65 (n, %)
601 (19.04)
531 (22.20)
70 (9.15)
Elixhauser Index (based on pre-CD-diagnosis period)
Score (mean, SD)
2.10 (2.42)
2.24 (2.50)
1.65 (2.11)
Score: 0 (n, %)
916 (29.01)
666 (27.84)
250 (32.68)
Score: 1-2 (n, %)
1,273 (40.32)
924 (38.63)
349 (45.62)
Score: >3 (n, %)
968 (30.66)
802 (33.53)
166 (21.70)
GI-Related Hospitalization Prior to Diagnosis
Prior Hospitalization (n, %)
278 (8.81)
216 (9.03)
62 (8.10)
CD-Related Surgical Procedures Performed Within 60 Days Following Index Diagnosis
Procedure Performed (n, %)
1,858 (58.85)
1,388 (58.03)
470 (61.43)
Diagnosis Year
2011
588 (18.63)
489 (20.44)
99 (12.94)
2012
524 (16.60)
415 (17.35)
109 (14.25)
2013
469 (14.86)
352 (14.72)
117 (15.29)
2014
357 (11.31)
258 (10.79)
99 (12.94)
2015
399 (12.64)
294 (12.29)
105 (13.73)
2016
438 (13.87)
321 (13.42)
117 (15.29)
2017
382 (12.10)
263 (10.99)
119 (15.56)

Significance
(Ha: SU≠TD)

p=0.0099
p<0.0001
p<0.0001

p<0.0001

p<0.0001

p<0.0001

p<0.0001
p<0.0001

p=0.4317
p=0.0951

p<0.0001

CD = Crohn’s Disease; SU = Step-Up Therapy; TD = Top-Down Therapy; ICD = International Classification of Diseases;
SD = Standard Deviation
Significance assessed with t-test and chi-squared tests comparing the SU and TD cohorts for each variable.
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Table 7: Crohn’s Disease, Step-Up, and Top-Down Cohort Cost and Utilization
Results Measured in the Follow-Up Period
CD Cohort
(Study Population)

SU Cohort

TD Cohort

Significance
(Ha: SU ≠ TD)

Cost (based on follow-up period)
Overall All-cause Cost (mean $, SD)

38,887
(83,818)

34,898
(88,168)

51,359
(66,988)

p<0.0001

CD-Specific Total Cost (mean $, SD)

16,830
(28,305)

11,765
(24,752)

32,664
(32,570)

p<0.0001

CD-Specific Healthcare Costs (mean $, SD)

6,321
(19,627)

4,616
(16,731)

11,653
(26,031)

p<0.0001

CD-Specific Medication Costs (mean $, SD)

10,414
(16,216)

7,025
(12,560)

21,011
(21,074)

p<0.0001

16.19
(14.78)

13.27
(13.23)

25.33
(15.63)

p<0.0001

CD-Specific Healthcare Utilization (mean, SD)

8.34
(11.27)

6.42
(9.92)

14.35
(12.99)

p<0.0001

CD-Specific Medication Utilization (mean, SD)

8.08
(6.84)

6.97
(6.34)

11.53 (7.18)

p<0.0001

Utilization (based on follow-up period)
CD-Specific Total Utilization (mean, SD)

CD = Crohn’s Disease; SU = Step-Up Therapy; TD = Top-Down Therapy; SD = Standard Deviation
Significance assessed with t-tests comparing the SU and TD cohorts for each variable.
Costs were standardized to the 2017 dollar using the Personal Health Care Expenditure deflator

Overall All-cause Cost: healthcare expenditures for any indication, encompassing all pharmacy, outpatient healthcare, laboratory
testing, imaging, and hospitalization/emergency department costs.
CD-Specific Total Cost/Utilization: sum of cost/prescriptions dispensed for CD-indicated therapies and cost/utilization of medical
visits and hospitalizations with a primary diagnosis of CD in the follow-up period.
CD-Specific Healthcare Cost/Utilization: Cost relating to/number of healthcare visits, including outpatient appointments,
laboratory tests, imaging, hospitalization/emergency department use, with CD as the primary diagnosis
CD-Specific Medication Cost/Utilization: Cost relating to/number of prescriptions dispensed for CD-indicated medications.
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Table 8:Direct, Per-Patient Average Disease-Specific Healthcare Costs for the
Crohn’s Disease, Step-Up, and Top-Down Cohorts
CD Cohort (n=3,157)
n

Average Cost
(SD)

SU Cohort (n=2,392)

p-value*

n

Average Cost
(SD)

TD Cohort (n=765)
n

Sex
Female
1,696
6,380 (20,724)
1,316
4,909 (18,075)
380
p=0.8557
Male
1,461
6,253 (18,277)
1,076
4,258 (14,924)
385
Age at Diagnosis
Age: 18-29 years
737
10,869 (25,457)
460
7,364 (18,919)
277
Age: 30-44 years
797
6,318 (18,609)
585
5,327 (17,748)
212
p<0.0001
Age: 45-64 years
948
4,325 (13,718)
755
3,146 (10,696)
193
Age: ≥ 65 years
675
4,164 (19,745)
592
3,652 (19,678)
83
Disease Location (ICD 9/10 Code)
Small Intestine
1,085
7,071 (21,609)
832
5,079 (16,692)
253
Large Intestine
719
3,450 (12,589)
585
2,771 (11,602)
134
p<0.0001
Small and Large
902
10,050 (24,579)
601
8,147 (23,835)
301
Intestine
Unspecified
451
1,637 (7,071)
374
799 (2,923)
77
Location
East North Central
567
6,432 (17,974)
403
4,431 (13,699)
164
East South Central
96
5,590 (18,319)
72
4,287 (15,322)
24
Middle Atlantic
218
7,361 (19,851)
173
4,016 (12,943)
45
Mountain
287
5,812 (17,578)
227
4,344 (15,102)
60
p=0.9542
New England
145
5,680 (13,828)
114
3,297 (11,139)
31
Pacific
339
5,401 (17,543)
266
3,820 (14,429)
73
South Atlantic
782
6,172 (18,316)
624
5,094 (16,227)
158
West North Central
352
6,804 (20,632)
231
5,580 (22,047)
121
West South Central
371
7,072 (27,664)
282
4,988 (23,177)
89
Payer
Commercial
2,444
7,021 (19,777)
1,770
5,015 (15,838)
674
p=0.0006
Medicare, Age < 65
112
2,188 (6,060)
91
1,705 (4,464)
21
Medicare, Age ≥ 65
601
4,246 (20,429)
531
3,784 (20,482)
70
Elixhauser Index (based on pre-CD-diagnosis period)
Score: 0
916
6,759 (20,125)
666
4,440 (14,836)
250
p=0.5287
Score: 1-2
1,273
6,431 (18,428)
924
5,503 (16,382)
349
Score: <3
968
5,764 (20,659)
802
4,258 (18,526)
166
GI-Related Hospitalization Prior to Diagnosis
Prior
278
10,143 (25,660)
216
10,019 (27,290)
62
Hospitalization
p=0.0007
No Prior
2,879
5,952 (18,908)
2,176
4,080 (15,196)
703
Hospitalization
CD-Related Surgical Procedures Performed Within 60 Days Following Index Diagnosis
Procedure
1,858
6,870 (20,083)
1,388
5,034 (17,437)
470
Performed
p=0.0603
No Procedure
1,299
5,536 (18,936)
1,004
4,308 (15,693)
295
Performed
Diagnosis Year
2011
588
4,871 (19,281)
489
3,341 (11,906)
99
2012
524
5,272 (15,661)
415
4,290 (14,822)
109
2013
469
6,619 (21,098)
352
5,694 (20,139)
117
p=0.0741
2014
357
8,132 (21,537)
258
5,422 (17,782)
99
2015
399
6,219 (16,356)
294
3,901 (13,422)
105
2016
438
8,086 (25,513)
321
6,419 (24,390)
117
2017
382
6,019 (16,239)
263
3,867 (12,304)
119

Average Cost
(SD)

11,477 (27,454)
11,828 (24,582)
16,688 (32,840)
9,050 (20,599)
8,937 (21,263)
7,819 (19,952)
13,625 (32,150)
6,413 (15,928)
13,849 (25,620)
5,712 (15,292)
11,350 (24,995)
9,502 (25,300)
20,221 (32,793)
11,367 (24,177)
14,446 (18,693)
11,161 (25,210)
10,431 (24,516)
9,141 (17,467)
13,673 (38,005)
12,289 (26,873)
4,281 (10,414)
7,748 (19,812)
12,934 (29,116)
10,078 (22,608)
13,037 (27,763)
10,574 (19,097)
11,749 (26,565)

12,292 (25,658)
10,637 (26,630)
12,429 (38,100)
9,013 (18,100)
9,401 (23,626)
15,192 (28,037)
12,712 (21,413)
12,658 (27,970)
10,775 (21,958)

CD = Crohn’s Disease; SU = Step-Up Therapy; TD = Top-Down Therapy; ICD = International Classification of Diseases;
SD = Standard Deviation
Crohn’s Disease-Specific Healthcare Costs was used for calculations, which represents all medical costs, without medication costs.
*Significance assessed with t-tests and analysis of variance (ANOVA) tests for variation between levels of the variables in the CD
cohort (study population).

54

Table 9:Results of Optimized General Linear Model Predicting Factors
Associated with Direct Crohn’s Disease-Specific Healthcare Expenditure
Adjusted
Ratio§
821.39

SE

Adjusted Ratio
95% CI*
(498.35, 1419.70)

Adjusted
Costs ($)

Intercept
1.30
Therapy Strategy
TD
2.50
1.09
(2.12, 2.95)
2,051.65
SU
Reference
Sex
Female
1.15
1.08
(1.00, 1.32)
943.79
Male
Reference
Age Group
Age: 18-29 years
3.70
1.28
(2.22, 5.84)
3,038.44
Age: 30-44 years
2.38
1.27
(1.43, 3.73)
1,952.96
Age: 45-64 years
1.86
1.27
(1.13, 2.89)
1,524.77
Age: ≥ 65 years
Reference
Disease Location (ICD 9/10 Code)
Small Intestine (555.0, K50.0)
1.99
1.10
(1.66, 2.40)
1,638.11
Large Intestine (555.1, K50.1)
Reference
Small and Large Intestine
3.07
1.10
(2.53, 3.72)
2,521.98
(555.2 K50.8)
Unspecified (555.9, K50.9)
0.43
1.13
(0.34, 0.54)
350.09
Payer
Commercial
Reference
Medicare, Age < 65
0.41
1.22
(0.28, 0.62)
337.17
Medicare, Age ≥ 65
1.45
1.27
(0.88, 2.27)
1,190.82
Elixhauser Index
Score: 0
Reference
Score: 1-2
1.00
1.09
(0.83, 1.19)
817.70
Score: ≤ 3
1.06
1.11
(0.86, 1.31)
868.88
GI-Related Hospitalization Prior to Diagnosis
Prior Hospitalization
2.80
1.14
(2.18, 3.63)
2,297.32
No Prior Hospitalization
Reference
CD-Related Surgical Procedures Performed Within 60 Days Following Index Diagnosis
Procedure Performed
0.91
1.08
(0.78, 1.05)
748.37
No Procedure Performed
Reference
Diagnosis Year
2011
Reference
2012
0.90
1.13
(0.71, 1.14)
739.52
2013
1.36
1.13
(1.07, 1.74)
1,121.03
2014
1.74
1.14
(1.34, 2.27)
1,428.67
2015
1.10
1.14
(0.86, 1.41)
901.00
2016
1.38
1.13
(1.08, 1.76)
1,132.29
2017
0.84
1.14
(0.66, 1.09)
692.36

% Difference
in Cost*‡

149.78%

14.90%

269.91%
137.76%
85.63%

99.43%
207.04%
-57.38%

-58.95%
44.98%

-0.45%
5.78%
179.69%

-8.89%

-9.97%
36.48%
73.93%
9.69%
37.85%
-15.71%

CD = Crohn’s Disease; SU = Step-Up Therapy; TD = Top-Down Therapy; ICD = International Classification of Diseases;
SD = Standard Deviation
Dependent Variable: Crohn’s Disease-Specific Healthcare Costs, which represents all medical costs, without medication costs.
§:Adjusted exponentiated β Coefficient exponentiated
*: Adjusted exponentiated values
‡: Percentage change in cost when all other independent variables are at the reference level.
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Table 10: Results of Full General Linear Model Predicting Factors Associated
with Direct Crohn’s Disease-Specific Healthcare Expenditure
AdjustedRatio§
859.37

Adjusted Ratio
95% CI*
(500.50, 1539.33)

SE

Adjusted
Costs ($)

Intercept
1.33
Therapy Strategy
TD
2.52
1.09
(2.14, 2.98)
2,164.40
SU
Reference
Sex
Female
1.13
1.08
(0.98, 1.31)
0,972.53
Male
Reference
Age Group
Age: 18-29 years
3.56
1.28
(2.13, 5.66)
3,060.70
Age: 30-44 years
2.25
1.28
(1.35, 3.55)
1,934.69
Age: 45-64 years
1.80
1.27
(1.09, 2.82)
1,550.29
Age: ≥ 65 years
Reference
Disease Location (ICD 9/10 Code)
Small Intestine (555.0, K50.0)
2.01
1.10
(1.67, 2.42)
1,726.76
Large Intestine (555.1, K50.1)
Reference
Small and Large Intestine
3.19
1.10
(2.62, 3.87)
2,739.69
(555.2 K50.8)
Unspecified (555.9, K50.9)
0.44
1.13
(0.34, 0.56)
373.98
Location
East North Central
0.87
1.14
(0.67, 1.13)
751.82
East South Central
0.97
1.26
(0.63, 1.55)
833.56
Middle Atlantic
0.98
1.19
(0.70, 1.38)
843.20
Mountain
1.07
1.17
(0.79, 1.45)
917.36
New England
0.71
1.21
(0.49, 1.05)
613.14
Pacific
0.83
1.16
(0.62, 1.11)
712.73
South Atlantic
1.10
1.13
(0.86, 1.41)
946.91
West North Central
1.04
1.16
(0.78, 1.36)
891.05
West South Central
Reference
Payer
Commercial
Reference
Medicare, Age < 65
0.43
1.22
(0.30, 0.65)
370.55
Medicare, Age ≥ 65
1.44
1.28
(0.87, 2.27)
1,240.91
Elixhauser Index
Score: 0
Reference
Score: 1-2
1.00
1.09
(0.84, 1.19)
0,856.03
Score: <3
1.01
1.12
(0.82, 1.26)
0,870.35
GI-Related Hospitalization Prior to Diagnosis
Prior Hospitalization
2.83
1.14
(2.21, 3.68)
2,434.51
No Prior Hospitalization
Reference
CD-Related Surgical Procedures Performed Within 60 Days Following Index Diagnosis
Procedure Performed
0.94
1.08
(0.81,1.09)
804.56
No Procedure Performed
Reference
Diagnosis Year
2011
Reference
2012
0.87
1.13
(0.68, 1.10)
744.04
2013
1.37
1.13
(1.07, 1.76)
1,179.80
2014
1.72
1.14
(1.32, 2.25)
1,481.19
2015
1.07
1.14
(0.83, 1.38)
920.76
2016
1.40
1.14
(1.09, 1.80)
1,203.39
2017
0.84
1.14
(0.65, 1.09)
722.70

% Difference
in Cost*‡

151.86%

13.17%

256.16%
125.13%
80.40%

100.93%
218.80%
-56.48%
-12.51%
-3.00%
-1.88%
6.75%
-28.65%
-17.06%
10.19%
3.69%

-56.88%
44.40%

-0.39%
1.28%
183.29%

-6.38%

-13.42%
37.29%
72.36%
7.14%
40.03%
-15.90%

CD = Crohn’s Disease; SU = Step-Up Therapy; TD = Top-Down Therapy; ICD = International Classification of Diseases;
SD = Standard Deviation
Dependent Variable: Crohn’s Disease-Specific Healthcare Costs, which represents all medical costs, without medication costs.
§:Adjusted exponentiated β Coefficient exponentiated
*: Adjusted exponentiated values
‡: Percentage change in cost when all other independent variables are at the reference level.
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APPENDIX 2: FIGURES

Figure 1: Study Schematic
Pre-Diagnosis Period
(no Crohn’s Disease-Indicated Medications
Dispensed & No Crohn’s Disease Diagnosis Code)

Follow-up Period

Medication
Exposure Period

Day 60
Day -365

Index Diagnosis
(Day 0)
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365 Days
Day 425

Figure 2: Step-Up and Top-Down Cohort Selection Method

CD Cohort

CD-Rx
within 60 days following
index diagnosis

SU Cohort

CD-Rx
prior to index diagnosis or not
within 60 days following
index diagnosis
(excluded)

TD Cohort

CD: Crohn’s Disease; SU: Step-Up Therapy; TD: Top-down Therapy; Rx: Prescription Dispensed
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Figure 3: Population Flow Diagram
183,452 Patients Identified
with at least one CD diagnosis code between
2010 -2018

87,903 Patients Excluded for
not having two diagnosis codes at least 30 days
apart

95,549 Patients Identified
with two CD diagnosis codes during the study
period
4,710 Patients Excluded for
age <18 years of age at index diagnosis
90,839 Patients Identified
as ≥18 years of age at index diagnosis
20,431 Patients Excluded for
not having a CD indicated medication dispensed or
not having prescriptions dispensed data
70,408 Patients Identified
with an CD-indicated medication dispensed
after the index diagnosis date

39,207 Patients Excluded for
not having a CD-indicated medication dispensed in
the 60-day exposure period or having a dispense in
the pre-diagnosis period

31,201 Patients Identified
with a CD-indicated medication dispensed in
the 60-day exposure period and no dispense
in the pre-diagnosis period

25,343 Patients Excluded for
lack of continuous enrollment for one year before
the index diagnosis
5,858 Patients Identified
with continuous enrollment for one year before the index diagnosis
1,974 Patients Excluded for
lack of continuous enrollment for 425 days after index diagnosis
3,884 Patients Identified
with full enrollment for entire study period
727 Patients Excluded for
having comorbidities also treated with CD-indicated biologics during the study period

3,157 Patients Identified for analysis

SU Cohort:
2,392 Patients

TD Cohort:
765 Patients
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Figure 4: Percentage of Age Groups in Step-Up and Top-Down Cohorts
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Figure 5: Percentage of Step-Up and Top-Down Therapy Initiated by Year
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Figure 6A: Cost Variable Distributions for Study Cohorts

Figure 6B: Utilization Variable Distributions for Study Cohorts

62

Figure 7: Disease-Specific Healthcare Cost by Year/Over Time for the Crohn’s
Disease, Step-Up, and Top-Down Cohorts

Note: Crohn’s Disease-Specific Healthcare Costs is graphed, which represents all medical costs, without medication
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